Citigroup Issues Pessimistic Forecast for Stryker (NYSE:SYK) Stock Price

Stryker (NYSE:SYK) had its price target lowered by equities researchers at Citigroup from $399.00 to $360.00 in a research note issued to investors on Thursday, Benzinga reports. The brokerage currently has a “buy” rating on the medical technology company’s stock. Citigroup’s target price suggests a potential upside of 31.58% from the company’s previous close.

Several other research analysts also recently issued reports on SYK. UBS Group assumed coverage on shares of Stryker in a report on Tuesday, July 28th. They set a “buy” rating and a $400.00 price objective on the stock. Wall Street Zen raised Stryker from a “hold” rating to a “buy” rating in a report on Saturday, August 8th. Piper Sandler decreased their price objective on Stryker from $420.00 to $390.00 and set an “overweight” rating on the stock in a report on Friday, July 31st. Weiss Ratings reaffirmed a “hold (c)” rating on shares of Stryker in a research report on Friday, July 31st. Finally, Leerink Partners lowered their price target on shares of Stryker from $410.00 to $407.00 and set an “outperform” rating on the stock in a report on Friday, June 5th. Eighteen investment analysts have rated the stock with a Buy rating and six have issued a Hold rating to the company’s stock. According to MarketBeat, the company currently has an average rating of “Moderate Buy” and an average target price of $380.40.

Stryker Stock Performance

SYK traded down $1.79 during midday trading on Thursday, reaching $273.60. The company’s stock had a trading volume of 1,164,329 shares, compared to its average volume of 2,393,981. The company has a current ratio of 2.16, a quick ratio of 1.33 and a debt-to-equity ratio of 0.59. The company has a fifty day simple moving average of $326.77 and a 200 day simple moving average of $327.62. The stock has a market cap of $104.95 billion, a P/E ratio of 28.38, a PEG ratio of 1.73 and a beta of 0.76. Stryker has a twelve month low of $270.85 and a twelve month high of $392.55.

Stryker (NYSE:SYK) last posted its quarterly earnings data on Thursday, July 30th. The medical technology company reported $3.69 earnings per share for the quarter, beating the consensus estimate of $3.49 by $0.20. The company had revenue of $6.59 billion during the quarter, compared to analysts’ expectations of $6.58 billion. Stryker had a return on equity of 23.63% and a net margin of 14.43%.Stryker’s revenue for the quarter was up 9.4% compared to the same quarter last year. During the same period in the prior year, the business earned $3.13 earnings per share. Stryker has set its FY 2026 guidance at 14.950-15.100 EPS. Research analysts expect that Stryker will post 15.03 earnings per share for the current year.

Insider Activity

In related news, Director Ronda E. Stryker sold 50,000 shares of the business’s stock in a transaction that occurred on Wednesday, August 19th. The shares were sold at an average price of $340.10, for a total transaction of $17,005,000.00. Following the completion of the sale, the director directly owned 2,251,375 shares of the company’s stock, valued at $765,692,637.50. The trade was a 2.17% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available at this link. Also, insider Dylan Crotty sold 441 shares of the stock in a transaction that occurred on Friday, August 21st. The shares were sold at an average price of $328.61, for a total transaction of $144,917.01. Following the completion of the transaction, the insider owned 6,102 shares in the company, valued at $2,005,178.22. This represents a 6.74% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Insiders have sold 351,267 shares of company stock valued at $118,197,701 over the last three months. 4.60% of the stock is owned by insiders.

Institutional Investors Weigh In On Stryker

A number of institutional investors have recently made changes to their positions in the stock. The Manufacturers Life Insurance Company boosted its stake in Stryker by 8.2% during the 2nd quarter. The Manufacturers Life Insurance Company now owns 859,544 shares of the medical technology company’s stock worth $270,642,000 after acquiring an additional 65,333 shares during the last quarter. Palogic Value Management L.P. increased its holdings in shares of Stryker by 4.3% in the second quarter. Palogic Value Management L.P. now owns 1,313 shares of the medical technology company’s stock worth $413,000 after acquiring an additional 54 shares in the last quarter. Tidal Investments LLC raised its position in shares of Stryker by 174.2% during the second quarter. Tidal Investments LLC now owns 111,457 shares of the medical technology company’s stock worth $35,091,000 after purchasing an additional 70,805 shares during the period. Van Hulzen Asset Management LLC lifted its holdings in shares of Stryker by 3.3% during the 2nd quarter. Van Hulzen Asset Management LLC now owns 15,148 shares of the medical technology company’s stock valued at $4,769,000 after purchasing an additional 481 shares in the last quarter. Finally, National Pension Service grew its position in shares of Stryker by 2.4% in the 2nd quarter. National Pension Service now owns 721,186 shares of the medical technology company’s stock valued at $227,058,000 after purchasing an additional 16,962 shares during the period. 77.09% of the stock is owned by institutional investors and hedge funds.

About Stryker

Stryker Corporation is a global medical technology company headquartered in Portage, Michigan. The company develops and manufactures products used by hospitals, physicians and other healthcare providers across a range of medical specialties.

Stryker’s principal businesses include orthopaedics, medical and surgical equipment, and neurovascular products. Its offerings include joint replacement and trauma implants, spinal devices, surgical instruments, operating-room equipment, endoscopy systems, surgical navigation technologies, emergency-care products and devices used to treat neurovascular conditions such as stroke.

Founded in 1941 by Dr.